ReviewOncogene2004
Molecular interdiction of Src-family kinase signaling in hematopoietic cells.
Review in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- The role of the Src family kinase Lyn in the immunomodulatory activities of cathelicidin peptide LL-37 on monocytic cells.Journal of leukocyte biology · 2012Trial
- Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis.American journal of hematology · 2019Article
- c-Src kinase is involved in the tyrosine phosphorylation and activity of SLC11A1 in differentiating macrophages.PloS one · 2018Article
- Signaling pathways mediating chemokine induction in keratinocytes by cathelicidin LL-37 and flagellin.Journal of innate immunity · 2012Article
- Lipid raft-targeted Akt promotes axonal branching and growth cone expansion via mTOR and Rac1, respectively.Journal of neuroscience research · 2009Article
- Src family tyrosine kinases mediate contraction of rat isolated tail arteries in response to a hyposmotic stimulus.Journal of hypertension · 2007Article
- Nonreceptor tyrosine kinases in prostate cancer.Neoplasia (New York, N.Y.) · 2007Review
- Src kinase inhibition promotes the chondrocyte phenotype.Arthritis research & therapy · 2007Article
- The Role of Intracellular Sodium in the Regulation of NMDA-Receptor-Mediated Channel Activity and Toxicity.Molecular neurobiology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The ability of Src-family kinases (SFKs) to mediate signaling from cell surface receptors in hematopoietic cells is a function of their catalytic activity, location and binding partners. Kinase activity is regulated in the cell by kinases and phosphatases that alter the state of phosphorylation of key tyrosine residues and by protein binding partners that stabilize the kinase in active or inactive conformations or localize the enzyme to specific subcellular or submembrane domains. Kinase activity and function can be modulated experimentally through the use of small molecule inhibitors designed to directly target catalytic or binding domains or regulate the location of the protein by altering its state of acylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.